Cutting-edge | Anti-APOE antibodies effectively remove amyloid deposition

Amyloid deposits in the brain are one of the signature features of Alzheimer's patients, so there are a number of studies currently aimed at removing these amyloid deposits, one of which is to use monoclonal antibodies that bind to amyloid.
they stimulate small glial cells in the brain to remove amyloid deposits.
, however, this treatment is usually accompanied by an adverse reaction called ARIA.
ARIA is a amyloid-related imaging abnormality, which may be a sign of cerebral edema (ARIA-E) or micro-bleeding (ARIA-H).
this adverse reaction limits the dose of anti-amyloid antibodies to some extent.
, a team of researchers at the University of Washington and Denali Therapeutics found that a monoclonal antibody targeting APOE did not increase the risk of brain bleeding while effectively removing amyloid deposits from brain tissue and blood vessels in animal models.
researchers say it could be a safer potential treatment for Alzheimer's disease.
study was published in the latest issue of Science Translational Medicine.
ARIA may have been caused by an overly inflammatory response, the researchers speculate that if monoclonal antibodies can target a small portion of amyloid deposition, it may be able to prevent ARIA production while removing protein deposition.
study, scientists used a monoclonal antibody that targeted a specific form of APOE protein.
the apoE allegior gene is the largest genetic risk factor for late-onset Alzheimer's disease.
APOE protein also plays an important role in the formation of amyloid protein deposition.
single-clone antibody called HAE-4 targets APOE proteins that are present in small amounts in amyloid deposits.
In mouse animal models of Alzheimer's disease and cerebral amyloid vascular disease (CAA, a disease caused by amyloid protein deposition in blood vessels), HAE-4 antibodies were able to effectively remove amyloid deposition in brain tissue and blood vessels compared to anti-amyloid antibodies.
at the same time, there was no increased risk of micro-bleeding of blood vessels.
researchers also found that HAE-4 antibodies, like anti-amyloid proteins, initially trigger an immune response to amyloid deposition.
in mice treated with HAE-4 antibodies were eliminated within two months, while inflammation inspired by anti-amyloid antibodies persisted.
" for decades, researchers have been looking for treatments to remove amyloid from the brain, and recently we finally had some promising treatments in progress, but we've found complications like ARIA.
, senior author of the study and head of the Department of Neurology at the University of Washington, said: "We have opened up a new pathway by targeting APOE.
it appears to effectively remove amyloid protein from brain tissue and blood vessels while avoiding this potentially dangerous side effect.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
References: s1. Xiong et al., (2021). APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine, DOI: 10.1126/scitranslmed.abd7522. [2] Protein linked to Alzheimer's, strokes cleared from brain blood vessels. Retrieved February 18, 2021, from